Response to treatment following recently acquired hepatitis C virus infection in a multicentre collaborative cohort

Grants

Funding Acknowledgements

The InC3 Study is supported by the National Institute on Drug Abuse Award Number R01DA031056. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute on Drug Abuse or the National Institutes of Health. Hep-Net III was funded by the German Network of Competence on Viral Hepatitis (funded by the German Federal Ministry of Education and Research, grants 01KI0102, 01KI0401 and 01KI0601), Essex Pharma, MSD and Schering-Plough. Other research support includes NIH R01 DA15999-01 (GM, MH, GD), U19 AI066345 (AYK and BHM), R01 DA033541 (AYK), MOP-103138 and MOP-210232 (JB). JD, JG, RSD, GM, AL, MH and GD acknowledge fellowship support from the National Health and Medical Research Council. JB is supported by Fonds de la Recherche du Quebec - Sante Research Career Awards. JD, RSD and MH acknowledge the contribution to this work of the Victorian Operational Infrastructure Support Program (Department of Health, Victoria, Australia) to the Burnet Institute. The Kirby Institute is funded by the Australian Government Department of Health and Ageing. The views expressed in this publication do not necessarily represent the position of the Australian Government. None of the funding sources had any involvement in the conduct, analysis or reporting of the study.